دورية أكاديمية
أعرض في EDS

Na + ,K + -ATPase and Cardiotonic Steroids in Models of Dopaminergic System Pathologies.

التفاصيل البيبلوغرافية
العنوان: Na + ,K + -ATPase and Cardiotonic Steroids in Models of Dopaminergic System Pathologies.
المؤلفون: Markina AA; Biological Department, Saint Petersburg State University, Universitetskaya Emb. 7/9, 199034 Saint Petersburg, Russia.; Institute of Translational Biomedicine, Saint Petersburg State University, Universitetskaya Emb. 7/9, 199034 Saint Petersburg, Russia., Kazanskaya RB; Biological Department, Saint Petersburg State University, Universitetskaya Emb. 7/9, 199034 Saint Petersburg, Russia.; Research Center of Neurology, Volokolamskoye Ahosse 80, 125367 Moscow, Russia., Timoshina JA; Research Center of Neurology, Volokolamskoye Ahosse 80, 125367 Moscow, Russia.; Biological Department, Lomonosov Moscow State University, Leninskiye Gory 1, 119991 Moscow, Russia., Zavialov VA; Biological Department, Saint Petersburg State University, Universitetskaya Emb. 7/9, 199034 Saint Petersburg, Russia.; Institute of Translational Biomedicine, Saint Petersburg State University, Universitetskaya Emb. 7/9, 199034 Saint Petersburg, Russia., Abaimov DA; Research Center of Neurology, Volokolamskoye Ahosse 80, 125367 Moscow, Russia., Volnova AB; Biological Department, Saint Petersburg State University, Universitetskaya Emb. 7/9, 199034 Saint Petersburg, Russia., Fedorova TN; Research Center of Neurology, Volokolamskoye Ahosse 80, 125367 Moscow, Russia., Gainetdinov RR; Institute of Translational Biomedicine, Saint Petersburg State University, Universitetskaya Emb. 7/9, 199034 Saint Petersburg, Russia.; Saint Petersburg University Hospital, 199034 Saint Petersburg, Russia., Lopachev AV; Institute of Translational Biomedicine, Saint Petersburg State University, Universitetskaya Emb. 7/9, 199034 Saint Petersburg, Russia.; Research Center of Neurology, Volokolamskoye Ahosse 80, 125367 Moscow, Russia.
المصدر: Biomedicines [Biomedicines] 2023 Jun 25; Vol. 11 (7). Date of Electronic Publication: 2023 Jun 25.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: In recent years, enough evidence has accumulated to assert that cardiotonic steroids, Na + ,K + -ATPase ligands, play an integral role in the physiological and pathophysiological processes in the body. However, little is known about the function of these compounds in the central nervous system. Endogenous cardiotonic steroids are involved in the pathogenesis of affective disorders, including depression and bipolar disorder, which are linked to dopaminergic system dysfunction. Animal models have shown that the cardiotonic steroid ouabain induces mania-like behavior through dopamine-dependent intracellular signaling pathways. In addition, mutations in the alpha subunit of Na + ,K + -ATPase lead to the development of neurological pathologies. Evidence from animal models confirms the neurological consequences of mutations in the Na + ,K + -ATPase alpha subunit. This review is dedicated to discussing the role of cardiotonic steroids and Na + ,K + -ATPase in dopaminergic system pathologies-both the evidence supporting their involvement and potential pathways along which they may exert their effects are evaluated. Since there is an association between affective disorders accompanied by functional alterations in the dopaminergic system and neurological disorders such as Parkinson's disease, we extend our discussion to the role of Na + ,K + -ATPase and cardiotonic steroids in neurodegenerative diseases as well.
References: Neuropharmacology. 2013 Oct;73:327-36. (PMID: 23774137)
Mol Pharmacol. 2007 Jul;72(1):40-51. (PMID: 17400762)
Neuroscience. 2019 Feb 1;398:274-294. (PMID: 30031123)
J Neurochem. 2021 Aug;158(4):960-979. (PMID: 33991113)
J Diet Suppl. 2017 Sep 3;14(5):553-572. (PMID: 28301304)
Front Mol Neurosci. 2011 Nov 01;4:38. (PMID: 22065948)
J Biol Chem. 1998 Jan 9;273(2):784-92. (PMID: 9422732)
PLoS One. 2012;7(4):e35645. (PMID: 22563390)
Sci Rep. 2019 Oct 30;9(1):15627. (PMID: 31666560)
Neurosci Res. 2019 Sep;146:54-64. (PMID: 30296459)
Behav Brain Res. 2014 Oct 1;272:100-10. (PMID: 24983657)
J Neurosci. 2007 Jan 17;27(3):616-26. (PMID: 17234593)
Brain Res Bull. 2018 Mar;137:356-362. (PMID: 29374602)
Bipolar Disord. 2016 Aug;18(5):451-9. (PMID: 27393337)
Biol Psychiatry. 2018 Dec 1;84(11):827-837. (PMID: 28689605)
J Neurosci. 2007 Jun 27;27(26):6995-7005. (PMID: 17596448)
Exp Neurol. 2004 Jan;185(1):169-81. (PMID: 14697328)
Am J Psychiatry. 2008 Jul;165(7):820-9. (PMID: 18519522)
PLoS One. 2013;8(3):e60141. (PMID: 23527305)
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1637-42. (PMID: 18590792)
Epilepsia. 2015 Jan;56(1):82-93. (PMID: 25523819)
J Biol Chem. 2013 Jan 25;288(4):2734-43. (PMID: 23195960)
Int J Neuropsychopharmacol. 2017 Nov 1;20(11):877-885. (PMID: 29020306)
Biomolecules. 2020 Jul 24;10(8):. (PMID: 32722349)
Behav Brain Res. 2011 Jan 20;216(2):659-65. (PMID: 20850480)
J Immunol. 2008 Jun 1;180(11):7485-96. (PMID: 18490749)
J Neurochem. 1994 Sep;63(3):834-42. (PMID: 7914223)
Curr Med Chem. 2022;29(27):4631-4697. (PMID: 35170406)
Neuroreport. 1997 Sep 8;8(13):2971-6. (PMID: 9376541)
Evid Based Complement Alternat Med. 2012;2012:928643. (PMID: 22454690)
Arch Biochem Biophys. 2011 Apr 1;508(1):1-12. (PMID: 21176768)
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18144-9. (PMID: 22025725)
Brain Res Brain Res Rev. 1998 May;26(2-3):148-53. (PMID: 9651511)
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):888-94. (PMID: 20403403)
J Cereb Blood Flow Metab. 2003 Jan;23(1):62-74. (PMID: 12500092)
J Biol Chem. 2008 Dec 26;283(52):36441-53. (PMID: 18984584)
J Psychiatr Res. 2011 Feb;45(2):162-8. (PMID: 20627318)
Mol Cell Neurosci. 2003 Dec;24(4):1012-26. (PMID: 14697665)
Cell Biochem Funct. 2016 Jul;34(5):367-77. (PMID: 27338714)
Mol Neurobiol. 2021 Dec;58(12):6697-6711. (PMID: 34609698)
Food Chem Toxicol. 2021 Dec;158:112657. (PMID: 34740715)
EMBO J. 2015 Oct 1;34(19):2408-23. (PMID: 26323479)
J Physiol. 2013 Jul 1;591(13):3433-49. (PMID: 23652595)
Brain Res. 1990 Aug 27;526(1):8-16. (PMID: 2078820)
Eur J Pharmacol. 2004 May 25;492(2-3):143-7. (PMID: 15178358)
Cell. 2005 Jul 29;122(2):261-73. (PMID: 16051150)
Front Physiol. 2016 Aug 02;7:314. (PMID: 27531981)
J Neurochem. 2001 Oct;79(2):349-60. (PMID: 11677263)
Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8189-93. (PMID: 8396262)
Nat Neurosci. 1999 Jul;2(7):649-55. (PMID: 10404198)
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1261-4. (PMID: 16815616)
Neurosci Lett. 2019 Jul 27;706:158-163. (PMID: 31121284)
Ann Neurol. 2011 Oct;70(4):591-9. (PMID: 21796667)
Neuropharmacology. 2018 Sep 15;140:260-274. (PMID: 30099050)
Am J Physiol Renal Physiol. 2010 Jul;299(1):F77-90. (PMID: 20427472)
Eur J Pharmacol. 1994 May 23;257(3):243-8. (PMID: 7916300)
J Basic Clin Physiol Pharmacol. 2019 Dec 4;31(3):. (PMID: 31800394)
J Pharmacol Exp Ther. 2001 Sep;298(3):1150-3. (PMID: 11504813)
Nat Genet. 2012 Sep;44(9):1030-4. (PMID: 22842232)
Annu Rev Physiol. 2010;72:395-412. (PMID: 20148682)
J Pharmacol Exp Ther. 2012 Dec;343(3):596-607. (PMID: 22927545)
J Neurosci. 2009 Sep 2;29(35):11011-9. (PMID: 19726659)
Glia. 2016 Oct;64(10):1677-97. (PMID: 27458821)
J Neurochem. 1999 Jan;72(1):112-9. (PMID: 9886061)
Neuropharmacology. 2016 Feb;101:87-97. (PMID: 26363191)
BMC Neurosci. 2017 Sep 8;18(1):66. (PMID: 28886701)
Traffic. 2004 Dec;5(12):1006-16. (PMID: 15522101)
J Cereb Blood Flow Metab. 2012 Jul;32(7):1222-32. (PMID: 22434069)
Mol Biol Cell. 2005 Sep;16(9):4034-45. (PMID: 15975899)
Proc Natl Acad Sci U S A. 2021 Jan 7;118(1):. (PMID: 33318128)
Free Radic Res. 2003 Jun;37(6):597-601. (PMID: 12868486)
Neurochem Int. 2004 Oct;45(5):627-32. (PMID: 15234104)
Neuroscience. 2016 May 3;321:163-188. (PMID: 26314632)
Genes Dis. 2020 Jan 22;8(3):259-271. (PMID: 33997173)
Brain Pathol. 2003 Oct;13(4):473-81. (PMID: 14655753)
Int J Mol Sci. 2019 Jul 16;20(14):. (PMID: 31315267)
Metab Brain Dis. 2021 Jan;36(1):153-167. (PMID: 33057922)
Int J Biomed Sci. 2014 Jun;10(2):85-102. (PMID: 25018677)
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:73-82. (PMID: 23643758)
Lancet Neurol. 2014 May;13(5):503-14. (PMID: 24739246)
Clin Biochem. 2005 Jan;38(1):36-45. (PMID: 15607315)
Toxicol Appl Pharmacol. 2017 Mar 15;319:80-90. (PMID: 28185818)
Curr Pharm Des. 2018;24(3):359-364. (PMID: 29318961)
Sci Adv. 2022 Sep 30;8(39):eabp8701. (PMID: 36179023)
Mol Pharmacol. 2021 Mar;99(3):217-225. (PMID: 33495275)
Front Physiol. 2016 Jun 14;7:209. (PMID: 27378932)
Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6259-63. (PMID: 1648735)
Chem Biol Interact. 2019 May 25;305:134-147. (PMID: 30922767)
Nature. 1982 Dec 16;300(5893):650-2. (PMID: 6292738)
Am J Physiol Cell Physiol. 2000 Sep;279(3):C541-66. (PMID: 10942705)
J Affect Disord. 2021 Mar 1;282:1195-1202. (PMID: 33601696)
Br J Pharmacol. 2022 Apr;179(8):1512-1524. (PMID: 33644859)
J Clin Invest. 2018 Jun 1;128(6):2266-2280. (PMID: 29708514)
Cardiol Rev. 2003 Mar-Apr;11(2):73-93. (PMID: 12620132)
Neurochem Int. 2009 Dec;55(7):491-5. (PMID: 19447152)
Pharmacol Biochem Behav. 2022 Sep;219:173434. (PMID: 35901967)
Neurochem Int. 2011 Nov;59(6):779-86. (PMID: 21871514)
Sci Rep. 2016 Feb 25;6:22047. (PMID: 26911348)
Am J Psychiatry. 2000 Jul;157(7):1108-14. (PMID: 10873919)
Chem Biol Interact. 2017 May 1;269:67-79. (PMID: 28389404)
Eur J Pharmacol. 2003 Aug 8;474(2-3):223-6. (PMID: 12921866)
Neurochem Int. 2019 Sep;128:163-174. (PMID: 31009649)
Prog Neuropsychopharmacol Biol Psychiatry. 1995 Sep;19(5):955-62. (PMID: 8539431)
Compr Physiol. 2021 Dec 29;12(1):2659-2679. (PMID: 34964112)
Neuropharmacology. 2017 May 1;117:447-459. (PMID: 27789311)
Nat Neurosci. 2000 Mar;3(3):226-30. (PMID: 10700253)
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14085-90. (PMID: 19666602)
Biochemistry (Mosc). 2018 Feb;83(2):140-151. (PMID: 29618300)
J Neurochem. 2013 Sep;126(5):591-603. (PMID: 23786406)
Mol Neurobiol. 2020 Oct;57(10):4018-4030. (PMID: 32651756)
Food Chem Toxicol. 2019 Nov;133:110765. (PMID: 31430510)
Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2212-7. (PMID: 19164762)
Neuroscience. 2011 Dec 15;198:221-31. (PMID: 21884755)
Exp Cell Res. 2003 Aug 15;288(2):324-34. (PMID: 12915123)
J Pharmacol Exp Ther. 1990 May;253(2):620-7. (PMID: 2160003)
Cell Calcium. 2020 Mar;86:102156. (PMID: 31896530)
Mol Chem Neuropathol. 1997 May;31(1):65-72. (PMID: 9271006)
Transl Psychiatry. 2019 Jun 4;9(1):158. (PMID: 31164628)
Eur J Neurosci. 2009 Jan;29(2):287-306. (PMID: 19200235)
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):491-6. (PMID: 15608059)
Brain. 2014 Apr;137(Pt 4):1107-19. (PMID: 24613933)
معلومات مُعتمدة: 22-75-10131 Russian Science Foundation; 94030300 St. Petersburg State University
فهرسة مساهمة: Keywords: Na+,K+-ATPase; bipolar disorder; cardiotonic steroids; depression; dopamine; neurodegeneration
تواريخ الأحداث: Date Created: 20230729 Latest Revision: 20230731
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10377002
DOI: 10.3390/biomedicines11071820
PMID: 37509460
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9059
DOI:10.3390/biomedicines11071820